SAGE Therapeutics Inc (NASDAQ:SAGE) Holdings Lifted by California State Teachers Retirement System

California State Teachers Retirement System raised its stake in SAGE Therapeutics Inc (NASDAQ:SAGE) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,529 shares of the biopharmaceutical company’s stock after purchasing an additional 1,614 shares during the period. California State Teachers Retirement System owned 0.15% of SAGE Therapeutics worth $6,852,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. M&R Capital Management Inc. acquired a new stake in shares of SAGE Therapeutics during the fourth quarter worth $28,000. Benjamin F. Edwards & Company Inc. acquired a new stake in SAGE Therapeutics in the fourth quarter valued at $29,000. Daiwa Securities Group Inc. lifted its holdings in SAGE Therapeutics by 34.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 80 shares during the period. Creative Planning acquired a new stake in SAGE Therapeutics in the fourth quarter valued at $211,000. Finally, Pacer Advisors Inc. acquired a new stake in SAGE Therapeutics in the third quarter valued at $233,000.

SAGE Therapeutics stock traded down $2.94 during midday trading on Monday, hitting $167.66. 349,907 shares of the company were exchanged, compared to its average volume of 627,230. The firm has a market capitalization of $8.03 billion, a PE ratio of -20.75 and a beta of 2.91. SAGE Therapeutics Inc has a fifty-two week low of $79.88 and a fifty-two week high of $177.14.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.89) by ($0.49). The business had revenue of $0.27 million during the quarter. During the same period last year, the business posted ($1.75) EPS. On average, sell-side analysts anticipate that SAGE Therapeutics Inc will post -12.47 earnings per share for the current year.

A number of equities research analysts have commented on SAGE shares. Morgan Stanley reduced their target price on SAGE Therapeutics from $230.00 to $213.00 and set an “overweight” rating for the company in a report on Wednesday, December 19th. BidaskClub cut SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 22nd. ValuEngine cut SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Guggenheim initiated coverage on SAGE Therapeutics in a report on Friday, February 22nd. They issued a “buy” rating and a $205.00 price target for the company. Finally, Canaccord Genuity set a $220.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research note on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $201.45.

In other SAGE Therapeutics news, Director James M. Frates sold 7,500 shares of the business’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $134.81, for a total transaction of $1,011,075.00. Following the completion of the transaction, the director now owns 11,735 shares in the company, valued at approximately $1,581,995.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven M. Paul sold 60,421 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $161.28, for a total value of $9,744,698.88. Following the transaction, the director now owns 272,777 shares of the company’s stock, valued at approximately $43,993,474.56. The disclosure for this sale can be found here. Insiders sold a total of 175,811 shares of company stock valued at $27,771,729 over the last quarter. Company insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “SAGE Therapeutics Inc (NASDAQ:SAGE) Holdings Lifted by California State Teachers Retirement System” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/sage-therapeutics-inc-sage-position-boosted-by-california-state-teachers-retirement-system.html.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Story: What are the benefits of investing in REITs?

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.